A peptide-based vaccine targeting survivin (SurVaxM) was evaluated in combination with standard therapy in a phase II trial (NCT 02455557) in newly diagnosed GBM patients and compared to historical controls [69]. Here, BIRC5 is linked to glioblastoma.